Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.45 |
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 8/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13942558 | 0.92 | GPBAR1 (0.44) | SLC10A1GPBAR1LMNANT5ESMN1; SMN2 | |
| SCHEMBL13293168 | 0.86 | GPBAR1 (0.60) | GPBAR1LMNANT5ESMN1; SMN2 | |
| SCHEMBL5446921 | 0.86 | GPBAR1 (0.60) | GPBAR1LMNANT5ESMN1; SMN2 | |
| SCHEMBL14398336 | 0.86 | GPBAR1 (0.60) | GPBAR1LMNANT5ESMN1; SMN2 | |
| SCHEMBL5444255 | 0.85 | TDP1 (0.42) | SLC10A1GPBAR1TDP1PRKCD | |
| SCHEMBL14374286 | 0.85 | TDP1 (0.41) | SLC10A1GPBAR1TDP1PRKCD | |
| SCHEMBL13910764 | 0.84 | SLC10A1 (0.51) | SLC10A1GPBAR1LMNANT5ESMN1; SMN2 | |
| SCHEMBL13910807 | 0.84 | GPBAR1 (0.51) | SLC10A1GPBAR1LMNANT5ESMN1; SMN2 | |
| SCHEMBL10061312 | 0.84 | SLC10A1 (0.52) | SLC10A1GPBAR1LMNANT5ESMN1; SMN2 | |
| SCHEMBL14374284 | 0.84 | SLC10A1 (0.67) | SLC10A1GPBAR1LMNANT5ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232577-A1 | Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin | ADVANCED LIFE SCIENCES, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232577-A1 | Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin | ADVANCED LIFE SCIENCES, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232577-A1 | Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin | ADVANCED LIFE SCIENCES, INC. (US) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232577-A1 | Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin | BET1, PGGT1B, BRCA1 | SLC10A1 2120/4885GPBAR1 225/4885LMNA 4313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.